ITOS241220C1000
- 0.00
- 0.000.00%
ITeos Therapeutics Newsroom
Wells Fargo Maintains ITeos Therapeutics(ITOS.US) With Buy Rating, Cuts Target Price to $19
ITeos Therapeutics Price Target Lowered to $19 From $31 at Wells Fargo
Wells Fargo Maintains Overweight on ITeos Therapeutics, Lowers Price Target to $19
ITeos Therapeutics Price Target Maintained With a $21.00/Share by HC Wainwright & Co.
H.C. Wainwright Maintains ITeos Therapeutics(ITOS.US) With Buy Rating, Cuts Target Price to $21
Express News | HC Wainwright & Co. Reiterates Buy on ITeos Therapeutics, Maintains $21 Price Target
Strategic Focus on Belrestotug Drives Buy Rating for ITeos Therapeutics With Adjusted Price Target of $21
Express News | Iteos Therapeutics Inc : Piper Sandler Cuts Target Price to $16 From $36
ITeos Therapeutics Says Deprioritizing Cancer Drug Candidate Inupadenant
ITeos Therapeutics Presents Interim A2A-005 Clinical Trial Data
ITeos Therapeutics Presents Interim A2A-005 Clinical Trial Data, Translational, and Preclinical Data From Inupadenant at ESMO Immuno-Oncology Congress
Express News | Iteos Therapeutics Presents Interim a2a-005 Clinical Trial Data, Translational, and Preclinical Data From Inupadenant at Esmo Immuno-Oncology Congress
ITeos to Participate in Upcoming Investor Conferences
Roche Anti-TIGIT Therapy Fails to Extend Survival in Late-stage Lung Cancer Trial
ITeos Therapeutics, Inc. (NASDAQ:ITOS) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year
H.C. Wainwright Maintains ITeos Therapeutics(ITOS.US) With Buy Rating, Maintains Target Price $46
Leerink Partners Maintains ITeos Therapeutics(ITOS.US) With Buy Rating
Strategic Catalysts and Financial Stability Underpin Buy Rating for ITeos Therapeutics
Express News | Iteos Therapeutics Inc : JP Morgan Cuts Target Price to $22 From $24
ITeos Therapeutics | 10-Q: Q3 2024 Earnings Report